Research links diabetes drug to more deaths, heart failure

A group of Ontario researchers is calling into question the continued use of the controversial diabetes drug Avandia, saying a competing drug in the same class is as effective and less dangerous.

Researchers have found that a diabetes drug called Actos may be much safer than its counterpart

Researchers have found that a diabetes drug called Actos may be much safer than its counterpart

TORONTO — A group of Ontario researchers is calling into question the continued use of the controversial diabetes drug Avandia, saying a competing drug in the same class is as effective and less dangerous.

The scientists, from Toronto’s Institute for Clinical Evaluative Sciences, said people taking Actos or pioglitazone for Type 2 diabetes are 23 per cent less likely to be hospitalized for heart failure and 14 per cent less likely to die than people taking Avandia or rosiglitazone.

“I can’t imagine why a patient would want to take rosiglitazone (Avandia) or a doctor would want to prescribe rosiglitazone,” principal investigator Dr. David Juurlink said in an interview.

“It’s got no advantage — not even a theoretical one — over pioglitazone (Actos). And we have this emerging or this increasing body of evidence that it’s not as safe.

“And the safety signal here is not a trivial problem. Heart failure and death — that’s a big deal.”

The research, published in the medical journal BMJ (formerly the British Medical Association Journal), looked at the anonymous records of nearly 40,000 Ontarians aged 66 and older who took one or the other of the drugs from April 1, 2002 to March 31, 2008.

Previous work had identified that Avandia, made by GlaxoSmithKline, increased the risk of heart attack of people taking it.

And it wasn’t clear whether Actos, made by Japanese drug maker Takeda, did as well. Both medications are in the same class of drugs, sometimes called the glitazones or TZDs.

Juurlink and colleagues from ICES set out to see if the cardiac safety profiles of both drugs were similar or if one was safer than the other.

They found real differences in the rates of heart failure and death among people on Avandia.

For every 120 people taking Avandia rather than Actos for a year, one more person would be hospitalized with heart failure, the authors said.

And for every 269 people who took Avandia rather than Actos for the same period, one person would die.

Juurlink said those number are not inconsequential, because these drugs are taken by millions of people.

“That sounds like sort of a smallish number.

“But when you think about the huge numbers of patients who got these drugs, we’re talking about a lot of additional harm that could be caused or perhaps was caused by rosiglitazone rather than pio(glitazone),” he said.

GSK disputed the findings, saying other studies have determined Avandia is an important treatment option for appropriate patients.

“Overall we disagree with the conclusions reached by Juurlink et al.,” the company said in an emailed response for comment on the study.

GSK noted the type of study Juurlink and his co-authors conducted — one looking back at data, called an observational study — is not considered to be as persuasive as evidence that is derived from a randomized control trial, where similar patients are randomly assigned to one treatment or the other and followed forward.

Observational studies based on anonymous medical records can’t rule out the possibility that the people taking Avandia might have been sicker, the company said.

And other factors such as whether people actually took the prescribed medication faithfully can’t be determined.

Juurlink anticipated the criticism, and had a counter argument. He said what initially seemed like a surprising finding — no difference in rates of heart attacks between patients on Avandia and those on Actos — actually supports the contention the two groups of patients were similar, healthwise.

If the patients who were prescribed Avandia were sicker than those on Actos, you would have expected to see more heart attacks in the Avandia group, he said.

Dr. Hertzel Gerstein, a diabetes expert at McMaster University in Hamilton, said he still believes there could be factors that cannot be measured that are confounding or influencing the results in ways that are unfairly detrimental to Avandia.

Gerstein and a cardiovascular expert at McMaster, Dr. Salim Yusef, are conducting a clinical trial funded by GSK comparing the outcomes of diabetes patients taking Avandia, Actos or a placebo. They will enrol 16,000 participants globally.

“The jury is out for me,” he insisted. “I don’t know, and I’m willing to say I don’t know.”

“I’m taking the approach here until we know for sure, I’m not willing to make a strong determination one way or the other.”

Dr. Steven Nissen, chair of cardiovascular medicine at the famed Cleveland Clinic, said he found the Juurlink paper persuasive.

And he said he saw little need for the GSK-funded study, the findings of which won’t be available for several years.

“I don’t understand what the value is except that it protects the company during this period of time.

By the time that that study is done, both drugs will be generically available,” he said.

Nissen was the co-author of a 2007 study review published in the New England Journal of Medicine that raised the concerns about elevated risk of heart attack among Avandia users.

Just Posted

Alberta has made a more detailed framework for those looking to acquire an exemption to the mandatory indoor mask bylaw. (AP Photo/Eric Gay, File)
Alberta changes requirements for mask exemptions

Masks wearing has been recommended for almost a year and provincially mandated… Continue reading

Alberta’a chief medical officer of health Dr. Deena Hinshaw said Thursday that there are more than 328,000 vaccine appointments booked over the next seven days. (Photo by Chris Schwarz/Government of Alberta)
Alberta surpasses 2 million doses administered of COVID-19 vaccine

Red Deer down to 835 active cases of COVID-19

RCMP file photo (Photo by Jeff Stokoe/Advocate staff)
RCMP investigating shooting near Maskwacis

Maskwacis and Wetaskiwin RCMP are seeking public assistance after a shooting has… Continue reading

Rode
Smith among impressive group of RDC soccer Queens recruits

There have been a number of cases where younger girls have developed… Continue reading

Red Deer Public Schools is projecting a $4-million budget deficit for 2021-22 school year. (AP Photo/Gregory Bull)
Red Deer Public Schools prepares $124-million budget

$1 million COVID recovery plan to assist students

Bo’s Bar and Grill owner Brennen Wowk said the hospitality industry is looking for more clarity from the province around what conditions must be met to allow for restaurants reopening. (Advocate file photo)
Frustated restaurant owners want to know government’s reopening plan

Restaurant owners feel they are in lockdown limbo

Vancouver Canucks' Nils Hoglander, right, is checked by Calgary Flames goalie Jacob Markstrom during third-period NHL hockey action in Calgary, Thursday, May 13, 2021.THE CANADIAN PRESS/Jeff McIntosh
Lindholm, Tkachuk lead Calgary Flames in 4-1 win over Vancouver Canucks

Lindholm, Tkachuk lead Calgary Flames in 4-1 win over Vancouver Canucks

Chicago Bulls guard Zach LaVine, right, drives to the basket against Toronto Raptors center Khem Birch, left, and guard Jalen Harris during the first half of an NBA basketball game in Chicago, Thursday, May 13, 2021. (AP Photo/Nam Y. Huh)
LaVine, Markkanen lead Bulls past Raptors, 114-102

LaVine, Markkanen lead Bulls past Raptors, 114-102

NFL schedules get off to strong starts with Week 1 twinbills

NFL schedules get off to strong starts with Week 1 twinbills

The Saddledome, home of the Calgary Flames, is shown in Calgary, Thursday, March 12, 2020. The final three games of Canada's Secret Cup women's hockey tournament will be played in Calgary's NHL arena.THE CANADIAN PRESS/Jeff McIntosh
Secret Cup women’s tournament final games to be held in Calgary’s Saddledome

Secret Cup women’s tournament final games to be held in Calgary’s Saddledome

FILE - In this Thursday, July 18, 2019 file photo, Ron Francis talks to reporters in Seattle after he was introduced as the first general manager for Seattle's yet-to-be-named NHL hockey expansion team. Four years since George McPhee was a “puppet master” of the NHL leading up to the Vegas expansion draft, general managers approached this trade deadline with Seattle’s upcoming addition to the league in mind. While Kraken GM Ron Francis prepares – and maybe made a handshake deal or two already like McPhee did – Seattle was on his colleagues’ minds.(AP Photo/Ted S. Warren, File)
Kraken still plan to hire coach before expansion draft

Kraken still plan to hire coach before expansion draft

Alberta Premier Jason Kenney attends a news conference in Calgary on Tuesday, Sept. 15, 2020. Simmering internal discontent in his United Conservative caucus has boiled over into an open challenge to his leadership. THE CANADIAN PRESS/Todd Korol
Two Alberta UCP members kicked out of caucus after challenging Kenney’s leadership

Two Alberta UCP members kicked out of caucus after challenging Kenney’s leadership

Toronto Blue Jays' Lourdes Gurriel Jr. (13) celebrates in the outfield at the end of a baseball game against the Atlanta Braves Thursday, May 13, 2021, in Atlanta. (AP Photo/Ben Margot)
Bichette, Blue Jays rally again to beat Braves 8-4

Bichette, Blue Jays rally again to beat Braves 8-4

FILE - Jordan Spieth waits his turn to putt during the third round of the Valero Texas Open golf tournament in San Antonio, in this Saturday, April 3, 2021, file photo. Spieth will try to complete the career Grand Slam next week at the PGA Championship. (AP Photo/Michael Thomas, File)
Momentum for McIlroy, few others going into PGA Championship

Momentum for McIlroy, few others going into PGA Championship

Most Read